Asgard Therapeutics
Updated: March 18, 2026
Founders: Fábio Rosa, Cristiana Pires, Filipe Pereira
Country: Sweden | Funding: €36M (+)
Founded: 2018
Website: https://www.asgardthx.com/
Asgard Therapeutics has developed a reprogramming technology to generate functional immune cell types capable of triggering immune responses. Its approach utilizes the concept of a "Trojan horse" (TrojanDC), which can be administered to different patients, triggering the presentation of tumor (neo)antigens and activating personalized antitumor responses. It targets tumor heterogeneity and bypasses tumor immune evasion. Asgard's lead program, AT-108, is pioneering the development of a ready-to-use, personalized treatment applicable to a wide range of oncological diseases.
Founded: 2018
Website: https://www.asgardthx.com/
Asgard Therapeutics has developed a reprogramming technology to generate functional immune cell types capable of triggering immune responses. Its approach utilizes the concept of a "Trojan horse" (TrojanDC), which can be administered to different patients, triggering the presentation of tumor (neo)antigens and activating personalized antitumor responses. It targets tumor heterogeneity and bypasses tumor immune evasion. Asgard's lead program, AT-108, is pioneering the development of a ready-to-use, personalized treatment applicable to a wide range of oncological diseases.
